10-K: BrightSpring Health Services Reports Strong 2025 Growth

BrightSpring Health Services, Inc. reported significant revenue and profit growth in 2025, driven by its Pharmacy Solutions and Provider Services segments, alongside strategic divestitures and acquisitions.

Summary

• Total revenues increased by $2.8 billion, or 28.2%, to $12.9 billion for the year ended December 31, 2025, compared to $10.1 billion in 2024.
• Net income saw a substantial improvement, rising by $173.7 million from a net loss of $68.9 million in 2024 to a net income of $104.8 million in 2025.
• Adjusted EBITDA grew by $157.4 million, or 34.2%, reaching $617.6 million in 2025 from $460.2 million in 2024.
• Diluted income per share increased to $0.48 in 2025 from a diluted loss per share of $(0.34) in 2024.
• The company entered into a definitive agreement on January 17, 2025, to divest its Community Living business for $835 million in cash, expected to close in Q1 2026.
• Completed three acquisitions within the Provider Services segment in 2025 for approximately $247.0 million, including the Amedisys and LHC Branches Acquisition.
• Total outstanding debt decreased to $2,569.7 million as of December 31, 2025, from $2,683.3 million in 2024.
• Total liquidity, including cash and Revolving Credit Facility availability, increased to $565.58 million at year-end 2025 from $475.833 million at year-end 2024.
• The company is no longer a controlled company under Nasdaq rules as of the second fiscal quarter of 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong financial growth across key metrics, strategic portfolio optimization through divestitures and acquisitions, and demonstrated operational efficiencies, despite ongoing regulatory scrutiny and competitive pressures.

Positives

• Revenue grew significantly by 28.2% to $12.9 billion in 2025, indicating strong market penetration and demand for services.
• Net income improved substantially from a loss of $68.9 million in 2024 to a profit of $104.8 million in 2025, demonstrating enhanced profitability.
• Adjusted EBITDA increased by 34.2% to $617.6 million, reflecting strong operational performance and efficiency.
• The divestiture of the Community Living business for $835 million is expected to streamline service offerings, increase strategic focus, and augment revenue and Adjusted EBITDA growth rates.
• Successful completion of three Provider Services acquisitions in 2025, expanding geographic offerings and service capabilities.
• Debt reduction of approximately $113.6 million in 2025, improving the company's financial leverage to 2.99x from 4.16x.
• Increased total liquidity by 18.8% to $565.58 million, enhancing financial flexibility.
• Strong operational metrics include 99.99% pharmacy order accuracy, 99.34% order completeness, and a 94.3% infusion patient satisfaction score.
• Home-based primary care achieved a hospital readmission rate 35% lower than the national average, highlighting effective care models.
• Hospice services achieved an 87% overall rating of care, exceeding the national average of 81%.
• PMO-led continuous improvement program generated $84.7 million in annual savings in 2025, demonstrating operational efficiency.
• Employee compensation increased over 50% in the last four years, supporting talent attraction and retention, with approximately 70% retention of clinical positions in home health, hospice, and rehab care from December 2024 to December 2025.

Negatives

• Gross profit margin in the Pharmacy Solutions segment decreased to 8.2% in 2025 from 8.5% in 2024, due to mix shifts towards lower-margin specialty branded drugs and increased fulfillment costs.
• The company is subject to an ongoing DOJ and DEA investigation regarding potential violations of the False Claims Act and Controlled Substances Act related to Embrace Hospice services, which could result in substantial liabilities.
• The divestiture of the Community Living business is subject to customary closing conditions, including antitrust approvals, and may not occur on the agreed terms or within the expected timeframe, potentially impacting business and financial condition.
• The company's high level of indebtedness, despite recent reductions, still requires a substantial portion of cash flows for debt service payments, limiting funds for other corporate purposes.
• Variable rate indebtedness exposes the company to interest rate risk, with a hypothetical 1% increase in rates decreasing net income and cash flows by $10.2 million annually on the unhedged portion of debt.

Risks

• Operating in a highly competitive U.S. healthcare industry across both pharmacy and provider services.
• Inability to maintain relationships with existing patient referral sources or establish new ones.
• Changes to Medicare and Medicaid rates or payment methods, which could materially adversely affect business.
• Cost containment initiatives of third-party payors, including post-payment audits, could adversely impact financial results.
• Implementation of alternative payment models (ACOs, MCOs) may limit market share and adversely affect revenues.
• Changes in patient case mix, payor mix, payment methodologies, and decisions of third-party organizations may materially adversely affect business.
• Reliance on federal and state spending, budget decisions, and continuous governmental operations, which may fluctuate.
• Changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement may negatively impact profitability.
• Changes in relationships with pharmaceutical suppliers, including drug availability or pricing, could adversely affect business and financial results.
• Reliance on continual recruitment and retention of qualified personnel (nurses, pharmacists, therapists, caregivers, direct support professionals, and senior management).
• Subject to federal, state, and local laws governing employment practices; failure to comply or increased expenses could adversely impact operations.
• Results of operations fluctuate on a quarterly basis due to various factors including census, script volume, reimbursement rates, and labor costs.
• Business may be harmed by labor relation matters, including work stoppages and renegotiation of collective bargaining agreements.
• Limited ability to control reimbursement rates, making cost management critical for profitability.
• Delays in collection or non-collection of accounts receivable, particularly during business integration, could adversely affect liquidity.
• Failure to manage growth effectively, including acquisitions and organic expansion, may hinder business plan execution and service quality.
• Inability to provide consistently high quality of care could adversely impact business, reputation, and referrals.
• Damage to corporate reputation from adverse publicity, including negative social media, or changes in public perception of services.
• Existing customers not continuing or renewing contracts, or renewing at lower fee levels, could materially adversely affect business.
• Dependence on effective investment in, implementation of improvements to, and maintenance of information technology and other business systems, including risks from AI technologies.
• Security breaches, loss of data, and other disruptions could compromise sensitive information, leading to liability, litigation, and reputational damage.
• Risks related to credit card payments and other payment methods, including increased fees and fraud risk.
• Exposure to substantial malpractice or other similar claims, potentially exceeding insurance limits.
• Governmental inquiries, regulatory actions, and whistleblower lawsuits could adversely affect operating results, with insurance potentially not covering all claims.
• Current insurance program may expose the company to unexpected costs if losses are not covered or differ from estimates.
• Factors outside of control could require recording an asset impairment of goodwill.
• Pandemics, epidemics, or infectious disease outbreaks may adversely affect business.
• Inclement weather, natural disasters, acts of terrorism, riots, civil insurrection, social unrest, looting, protests, strikes, or street demonstrations may impact service delivery.
• Inability to adequately protect intellectual property rights could harm business.
• KKR Stockholder owns a significant portion of stock, and its interests may conflict with other stockholders.
• Substantial indebtedness requires dedication of cash flows to debt service, reducing funds for other purposes.
• Ability to incur substantially more debt, further increasing financial risks.
• Inability to generate sufficient cash to service all indebtedness may force asset dispositions or capital raises on unfavorable terms.
• Restrictive covenants in outstanding indebtedness may limit current and future operations.
• Variable rate indebtedness subjects the company to interest rate risk, potentially increasing debt service obligations.
• Financial institutions failing to extend credit under the Revolving Credit Facility or reducing the borrowing base could adversely affect liquidity.
• High indebtedness may hinder ability to negotiate favorable terms with suppliers.
• Additional costs associated with being a public company and management devoting substantial time to compliance.
• Failure to comply with requirements to design, implement, and maintain effective internal controls could have a material adverse effect on business and stock price.
• Dilution from future issuance of additional common stock in connection with incentive plans, acquisitions, or settlement of Tangible Equity Units.
• Tangible Equity Units may adversely affect the market price of common stock.
• Limited ability to raise capital in the future on favorable terms.
• No current plans to pay cash dividends on common stock.
• Dependence on subsidiaries for cash to fund operations and meet debt obligations.
• Anti-takeover provisions in organizational documents could delay or prevent a change of control.
• Exclusive forum provisions in Articles of Incorporation could limit stockholders' ability to bring suit in different judicial forums.
• Changes in tax laws or adverse outcomes from examination of tax returns could adversely affect business.

Future Outlook

The company expects the divestiture of its Community Living business to close in the first fiscal quarter of 2026, which will streamline service offerings and increase strategic focus on Senior and Specialty populations, augmenting expected Revenue and Adjusted EBITDA growth rates. It anticipates continued expansion of pharmacy capabilities, particularly in home and community-based settings, and further growth in provider services for medically complex patients. The company plans to leverage its Home-Based Primary Care, CCRx, and Clinical (Nursing) Hub capabilities to support integrated and value-based care models. Investments in automation, data, and technology systems are expected to continue to drive efficiency and future growth. The company also expects to continue selective and strategic expansion of its footprint within the United States through de novo investments.

Management Comments

• Our differentiated approach to care delivery, with an integrated and scaled model, addresses critical services that the highest-need and highest-cost patients require.
• The divestiture of the Community Living business provides for continuity of important intellectual and developmental disability services while the Company focuses on a concentrated group of customers, patients and stakeholders in the future.
• We believe the Company's streamlined service offerings will result in increased strategic focus, operational efficiencies, a refined payor mix, and greater clinical integration and business synergy across the Provider Services segment.
• Our dedicated clinicians, caregivers, field, corporate and other administrative support employees, managers, and leaders are the critical elements that have enabled us to build a differentiated healthcare platform of scale with strong quality outcomes and historical financial performance.
• Operational excellence is a focus of our Company. It is a key aspect of our performance, and we believe it will be a driver of our continued growth.
• We believe our platform can continue to build further scale nationally, adding density to additional and targeted key markets as a lever to facilitate maximum pharmacy and provider services overlap, integrated and value-based care, and growth.

Industry Context

StockSavvy.ai notes that BrightSpring Health Services operates in a growing segment of the U.S. healthcare market, focusing on home and community-based care for complex patients. The shift towards value-based care and lower-cost settings, as highlighted by the company's strategy, aligns with broader industry trends driven by government and commercial payors. The company's integrated pharmacy and provider services model positions it well to address the needs of an aging population and those with chronic conditions, a demographic segment expected to drive significant future healthcare expenditures. The divestiture of the Community Living business reflects a strategic move to refine its focus within this evolving landscape, concentrating on higher-growth and clinically integrated opportunities. However, the industry remains highly competitive and heavily regulated, with ongoing scrutiny on drug pricing and payment models, which could impact profitability and market share.

Comparison to Industry Standards

• The company's pharmacy services achieve 99.99% order accuracy and 99.34% order completeness, which are described as 'excellent and world class NPS' (Net Promoter Score) and are strong indicators of quality compared to industry averages.
• Infusion patient satisfaction scores of 94.3% are in-line with the 95.6% national average, demonstrating competitive service quality in this specialized area.
• The company's hospice services boast an 87% overall rating of care, outperforming the national average of 81% as reported by the Agency for Healthcare Research and Quality.
• Home-based primary care shows a hospital readmission rate 35% lower than the national average, indicating superior outcomes in managing complex patients at home.
• For I/DD patients, the company has achieved reductions in hospitalizations and readmissions of 44% and 84% respectively since implementing home-based primary care services, significantly exceeding typical outcomes for this vulnerable population.
• 91% of the company's home health branches have a STAR rating of 4 or higher, suggesting a high level of quality compared to Centers for Medicare & Medicaid Services (CMS) benchmarks for home health agencies.

Management Changes

Corporate Governance

Legal Proceedings

• The Silver matter, a qui tam action alleging violations of the federal False Claims Act and state false claims acts against PharMerica, was settled for $120.0 million ($110.0 million paid in 2024, $10.0 million in 2025) and dismissed with prejudice on July 3, 2024.
• An ongoing investigation by the DOJ and DEA into Embrace Hospice for potential violations of the False Claims Act, Controlled Substances Act, and other laws, including allegations related to hospice services not being reasonable and medically necessary.
• Subject to various governmental reviews, audits, and investigations (e.g., RAC, TPE, UPIC programs) to verify compliance with Medicare and Medicaid programs and applicable laws.
• Exposure to lawsuits, civil investigative demands, and subpoenas under the False Claims Act, Controlled Substances Act, Anti-Kickback Statute, and Stark Law.
• Currently subject to class actions, employee-related claims (e.g., wage and hour laws, wrongful discharge, retaliation, discrimination), and other lawsuits.
• Involved in litigation regarding the use of the 'BrightSpring' mark, which if adversely determined, could result in monetary damages and cessation of use.

Related Party Transactions

• The Monitoring Agreement with KKR and Walgreens Boots Alliance, Inc. (WBA) was terminated upon the completion of the IPO in January 2024, resulting in a payment of $22.7 million in termination fees to KKR and WBA.
• KKR Capital Markets LLC (KCM), a KKR subsidiary, acted as an underwriter in the January 2024 IPO Offerings, receiving $7.4 million in underwriting discounts and commission.
• KCM also received $3.7 million in 2024 and $2.4 million in 2023 for underwriter, arranger, and transaction fees related to debt refinancing and Revolver upsize; no similar fees were paid in 2025.
• WBA sold its remaining ownership interests in the company through open market transactions during the second fiscal quarter of 2025 and is no longer considered a related party.
• The WBAD Membership Agreement with WBA and AmeriSourceBergen Drug Corporation (ABDC) for inventory purchases was terminated in Q1 2025, and a separate agreement was entered into with ABDC on February 1, 2025.
• KKR Stockholder beneficially owns approximately 32.2% of the voting power of the company's common stock, influencing director elections and corporate policies.

Stakeholder Impact

• **Shareholders**: Experienced positive financial returns with significant increases in net income and EPS. However, potential future dilution from equity issuances and the influence of KKR's significant ownership are factors. The anti-takeover provisions may limit opportunities for premium acquisition offers.
• **Employees**: Benefit from increased investments in compensation and benefits (over 50% increase in four years) and innovative technology solutions like daily pay. The company's focus on recruiting, training, and career pathways aims to improve retention and job satisfaction, but labor shortages remain a risk.
• **Customers/Patients**: Continue to receive high-quality, integrated care in home and community settings, evidenced by high satisfaction scores and improved health outcomes (e.g., lower hospital readmission rates). The strategic focus on Senior and Specialty populations aims to enhance service delivery.
• **Suppliers**: Relationships with pharmaceutical suppliers are critical, and the company's high indebtedness could potentially impact its ability to negotiate favorable terms, although current supply chain efforts have mitigated inflationary impacts.
• **Creditors**: The company's substantial debt requires significant cash flow for debt service, and restrictive covenants in debt agreements impose limitations on operations. However, recent debt reduction and increased liquidity are positive indicators for creditors.

Next Steps

• Close the divestiture of the Community Living business in the first fiscal quarter of 2026.
• Complete the purchase price allocation for the Amedisys and LHC Branches Acquisition by December 1, 2026.
• Continue to expand pharmacy capabilities, particularly in home and community-based settings.
• Further build out Home-Based Primary Care, transitional care management programs (CCRx), and Clinical (Nursing) Hub services.
• Continue investments in automation, data, and technology systems.
• Selectively and strategically expand the company's footprint within the United States through de novo investments.
• Comply with all applicable corporate governance requirements of Nasdaq, now that the company is no longer a controlled company.

Key Dates

Recommendation

The company demonstrated strong financial performance in 2025 with significant revenue, net income, and Adjusted EBITDA growth. The strategic divestiture of the Community Living business and focus on higher-growth segments, coupled with successful acquisitions and debt reduction, indicate a positive trajectory. While regulatory risks and competitive pressures exist, the company's operational efficiencies, high-quality care metrics, and integrated service model position it favorably for continued growth and market leadership in the evolving healthcare landscape. The improved profitability and financial health make it an attractive investment.

Keywords

Healthcare Services, Pharmacy Solutions, Provider Services, Home Health, Hospice, Rehab Care, Specialty Pharmacy, SEC Filing, 10-K, Financial Performance, Acquisitions, Divestiture, Debt Management, Corporate Governance, Risk Management, Medicare, Medicaid, Nasdaq, BTSG